2-乙基-7-甲氧基苯并呋喃 | 102234-44-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 中文名称: 2-乙基-7-甲氧基苯并呋喃
• 英文名称: 2-ethyl-7-methoxybenzo[b]furan
• 英文别名: 2-ethyl-7-methoxybenzofuran；2-Aethyl-7-methoxy-benzofuran；2-ethyl-7-methoxy-1-benzofuran
• CAS: 102234-44-6
• 化学式: C₁₁H₁₂O₂
• mdl: MFCD00060517
• 分子量: 176.215
• InChiKey: WWEPPXYVWNVLGW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.272
• 拓扑面积：
  22.4
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-乙基-7-甲氧基苯并呋喃 在 溴 、 四氯化锡 、 溶剂黄146 、 乙硫醇钠 作用下， 以 二硫化碳 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 0.41h， 生成 (6-bromo-2-ethyl-7-hydroxybenzofuran-4-yl)(4-methoxyphenyl)methanone
  参考文献：
  名称：

  Developing Potent Human Uric Acid Transporter 1 (hURAT1) Inhibitors

  摘要：

  The kidneys are a vital organ in the human body. They serve several purposes including homeostatic functions such as regulating extracellular fluid volume and maintaining acid-base and electrolyte balance and are essential regarding the excretion of metabolic waste. Furthermore, the kidneys play an important role in uric acid secretion/reabsorption. Abnormalities associated with kidney transporters have been associated with various diseases, such as gout. The current study utilized Xenopus oocytes expressing human uric acid transporter 1 (hURAT1; SLC22A12) as an in vitro method to investigate novel compounds and their ability to inhibit (14)C-uric acid uptake via hURAT1. We have prepared and tested a series of 2-ethyl-benzofuran compounds and probed the hURAT1 in vitro inhibitor structure activity relationship. As compared to dimethoxy analogues, monophenols formed on the C ring showed the best in vitro inhibitory potential. Compounds with submicromolar (i.e., IC(50) < 1000 nM) inhibitors were prepared by brominating the corresponding phenols to produce compounds with potent uricosuric activity.

  DOI：

  10.1021/jm1015022
• 作为产物：
  描述：

  2-乙酰基-7-甲氧基苯并呋喃 在 三甲基氯硅烷 、 3 A molecular sieve 、 sodium cyanoborohydride 作用下， 以 乙腈 为溶剂， 反应 24.0h， 以80%的产率得到2-乙基-7-甲氧基苯并呋喃
  参考文献：
  名称：

  NaBH 3 CN-TMSCl对酰基苯并[b]呋喃，芳香族醛和酮的还原性，选择性脱氧

  摘要：

  芳香醛，酮和酰基苯并[b]呋喃已用氰基硼氢化钠和温和的亲电子试剂三甲基氯硅烷进行了还原脱氧。

  DOI：

  10.1016/s0040-4039(98)01519-6

文献信息

• Synthesis and aldose reductase-inhibitory activity of benzo(b)furan derivatives possessing a carboxymethylsulfamoyl group.
  作者：Yoshitaka OHISHI、Teruo MUKAI、Michiko NAGAHARA、Motoyuki YAJIMA、Norio KAJIKAWA

  DOI：10.1248/cpb.37.2398

  日期：——

  Various benzo[b]futran derivatives with a carboxymethylsulfamoyl group were prepared and evaluated for aldose reductase-inhibitory potency. Most of the compounds displayed significant inhibitory activities (IC50, 10-8-10-7M). Among the test compounds, the compounds having a carboxymethylsulfamoyl group at the 3- or 4-position exhibited the greatest inhibitory potency. Structure-activity trends of the tested compounds are discussed.

  合成了多种含有羧甲基磺酰胺基团的苯并[b]呋喃衍生物，并对其对醛糖还原酶的抑制活性进行了评估。大多数化合物表现出显著的抑制活性（IC50，10^-8-10^-7M）。在测试的化合物中，位于3位或4位的羧甲基磺酰胺基团的化合物表现出最强的抑制活性。讨论了测试化合物的结构-活性趋势。
• A new course of the Perkin cyclization of 2-(2-formyl-6-methoxyphenoxy)alkanoic acids. Synthesis of 2-alkyl-7-methoxy-5-nitrobenzo[b]furans
  作者：Monika Kowalewska、Halina Kwiecień

  DOI：10.1016/j.tet.2008.03.067

  日期：2008.5

  4]-dioxepin-5-yl acetate and 2-alkyl-5-hydroxy-9-methoxy-7-nitro-5H-benzo[e][1,4]-dioxepin-3-one were formed as a result of the cyclization of 2-(2-formyl-6-methoxy-4-nitrophenoxy)alkanoic acids under classical Perkin reaction conditions. The products were characterized by spectroscopic methods and the mechanism of the cyclization is discussed.

  2-烷基-7-甲氧基-5-硝基苯并[ b ]呋喃，2-烷基-9-甲氧基-7-硝基-3-氧代-2,3-二氢-5 H-苯并[ e ] [1,4]环化的结果是形成乙酸-二氧杂戊基-5-基酯和2-烷基-5-羟基-9-甲氧基-7-硝基-5 H-苯并[ e ] [1,4]-二氧杂-3-基经典珀金反应条件下制备2-（2-甲酰基-6-甲氧基-4-硝基苯氧基）链烷酸 用光谱方法对产物进行了表征，并讨论了环化的机理。
• Method for Producing Aromatic Compound Polymer
  申请人：Higashimura Hideyuki

  公开号：US20090018309A1

  公开（公告）日：2009-01-15

  A method for producing an aromatic compound polymer comprising oxidatively polymerizing one or more of aromatic compound(s) having two or more hydrogen atoms directly connected to aromatic ring(s), in the presence of an oxidizing agent, wherein the method employs a catalyst composed of a transition metal complex or a catalyst prepared from a transition metal complex and an activating agent, and said catalyst has a parameter P defined by the following formula (A) of 0.50 or more, and a parameter Eo defined by the following formula (B) of 0.50 [V] or more: P=Af/Ai (A) and Eo =( Epa+Epc )/2[V]  (B).

  一种生产芳香族化合物聚合物的方法，包括在氧化剂存在下氧化聚合具有两个或更多氢原子直接连接到芳香环的一个或多个芳香族化合物，其中该方法采用由过渡金属配合物或由过渡金属配合物和活化剂制备的催化剂，所述催化剂具有以下公式（A）定义的参数P，P的值为0.50或更高，并且具有以下公式（B）定义的参数Eo，Eo的值为0.50 [V]或更高：P=Af/Ai（A）和Eo=(Epa+Epc)/2[V]（B）。
• INHIBITORS OF FILOVIRUS ENTRY INTO HOST CELLS
  申请人：Basu Arnab

  公开号：US20120189614A1

  公开（公告）日：2012-07-26

  Organic compounds showing the ability to inhibit viral glycoprotein (GP)-mediated entry of a filovirus into a host cell are disclosed. The disclosed filovirus entry inhibitor compounds are useful for treating, preventing, or reducing the spread of infections by filovirus including the type species Marburg virus (MARV) and Ebola virus (EBOV). Preferred inhibitors of the invention provide therapeutic agents for combating the Ivory Coast, Sudan, Zaire, Bundibugyo, and Reston Ebola virus strains.

  本发明揭示了有机化合物，表现出抑制病毒糖蛋白（GP）介导的菲罗病毒进入宿主细胞的能力。所揭示的菲罗病毒进入抑制剂化合物可用于治疗、预防或减少菲罗病毒感染的传播，包括类型种马尔堡病毒（MARV）和埃博拉病毒（EBOV）。本发明的优选抑制剂为治疗象牙海岸、苏丹、扎伊尔、邦迪布吉奥和雷斯顿埃博拉病毒株提供治疗剂。
• DEVELOPING POTENT URATE TRANSPORTER INHIBITORS: COMPOUNDS DESIGNED FOR THEIR URICOSURIC ACTION
  申请人：Wempe Michael F.

  公开号：US20130225673A1

  公开（公告）日：2013-08-29

  A compound represented by the general Formula I: a pharmaceutically acceptable salt or ester thereof, a solvate thereof, a chelate thereof, a non-covalent complex thereof, a pro-drug thereof, a deuterated radio-labeled analog thereof, and mixtures of any of the foregoing, wherein: A-K are individually selected from carbon or nitrogen; X═—O, —NR 1 , or —S; R 1-11 are individually selected from the group consisting of —H, C 1 -C 6 alkyl, C 6 -C 14 aryl, substituted C 6 -C 14 aryl, C 1 -C 14 -alkoxy, halogen, hydroxyl, carboxy, cyano, C 1 -C 6 -alkanoyloxy, C 1 -C 6 -alkylthio, C 1 -C 6 -alkylsulfonyl, trifluoromethyl, hydroxy, C 2 -C 6 -alkoxycarbonyl, C 2 -C 6 -alkanoylamino, —O—R 12 , S—R 12 , —SO 2 —R 12 , —NHSO 2 R 12 and —NHCO 2 R 12 , wherein R 12 is phenyl, naphthyl, or phenyl or naphthly substituted with one to three groups selected from C 1 -C 6 -alkyl, C 6 -C 10 aryl, C 1 -C 6 -alkoxy and halogen, and C 4 -C 20 hydroxyheteroaryl wherein the heteroatoms are selected from the group consisting of sulfur, nitrogen, and oxygen.

  一种由通式I表示的化合物：其中，该化合物为药学上可接受的盐或酯、溶剂化物、螯合物、非共价复合物、前药、氘标记的放射性类似物或任何上述物质的混合物，其中：A-K分别选择自碳或氮；X═—O、—NR1或—S；R1-11分别选择自—H、C1-C6烷基、C6-C14芳基、取代的C6-C14芳基、C1-C14烷氧基、卤素、羟基、羧基、氰基、C1-C6-烷酰氧基、C1-C6-烷基硫基、C1-C6-烷基磺酰基、三氟甲基、羟基、C2-C6-烷氧羰基、C2-C6-烷酰胺基、—O—R12、S—R12、—SO2—R12、—NHSO2R12和—NHCO2R12，其中R12为苯基、萘基或苯基或萘基，且其上选择了一到三个来自C1-C6烷基、C6-C10芳基、C1-C6烷氧基和卤素的基团以及C4-C20羟基杂芳基，其中杂原子选择自硫、氮和氧。